Unit of Metabolism, Cruces University Hospital, Biocruces Bizkaia Health Research Institute, GCV-CIBER de Enfermedades Raras (CIBERER), Plaza de Cruces s/n, Barakaldo, 48903, Spain; University of the Basque Country (UPV/EHU), Metab-European Reference Network, Spain.
Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), A Choupana, s/n, Santiago de Compostela, A Coruña, 15706, Spain.
Clin Nutr. 2020 Feb;39(2):455-459. doi: 10.1016/j.clnu.2019.02.019. Epub 2019 Feb 15.
Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation affecting >5% of the liver volume that is not explained by alcohol abuse. It is known that fructose gives rise to NAFLD and it has been recently described that the ingestion of fructose in low amounts in aldolase B deficient mice is associated with the development of fatty liver. Therefore, it is reasonable that patients with HFI (Hereditary Fructose Intolerance) present fatty liver at diagnosis, but its prevalence in patients treated and with adequate follow-up is not well documented in the literature. The aim of this study is to analyze the association between HFI and NAFLD in treated patients.
A cross-sectional observational study was conducted. The population comprised 16 genetically diagnosed HFI patients aged from 3 years to 48 and in dietary treatment of fructose, sorbitol and sacarose exclusion at least for two years. Blood samples were obtained for analytical studies and anthropometric measurements of each patient were performed.
Patients presented a Body Mass Index (BMI) of 17.9 ± 2.9 kg/m. The HOMA index and Quick index were in normal range for our population. The S-adenosyl-methionine (SAM)/S-adenosyl-l-homocysteine (SAH) ratio was increased in the patients in whom this analysis was performed. By imaging techniques it was observed that 9 of the 16 patients presented fatty liver (7 by hepatic MRI). Of these 9 patients, only 3 presented hepatomegaly. 7 of 9 patients affected by the c.448G > C mutation had fatty infiltration, of which three of them presented in addition hepatomegaly.
There is a high prevalence of fatty liver in HFI patients and it is not related to obesity and insulin resistance. The diagnosis of fatty liver in HFI patients and, above all, the identification of new therapeutic approaches, can positively impact the quality of life of these patients.
非酒精性脂肪性肝病(NAFLD)的特征是肝内脂肪堆积,超过肝脏体积的 5%,且无法用酒精滥用来解释。已知果糖会导致 NAFLD,最近有研究描述称,在醛缩酶 B 缺乏的小鼠中,低剂量摄入果糖与脂肪肝的发展有关。因此,患有遗传性果糖不耐受(HFI)的患者在诊断时出现脂肪肝是合理的,但在接受治疗且有充分随访的患者中,其患病率在文献中并未得到很好的记录。本研究旨在分析 HFI 与治疗患者中 NAFLD 的关系。
进行了一项横断面观察性研究。该人群包括 16 名遗传性诊断为 HFI 的患者,年龄 3 岁至 48 岁,接受果糖、山梨醇和蔗糖排除饮食治疗至少两年。采集血液样本进行分析研究,并对每位患者进行人体测量学测量。
患者的体重指数(BMI)为 17.9±2.9kg/m²。HOMA 指数和快速指数在我们人群的正常范围内。接受分析的患者中 S-腺苷甲硫氨酸(SAM)/S-腺苷同型半胱氨酸(SAH)比值升高。通过影像学技术观察到,16 名患者中有 9 名(7 名通过肝脏 MRI)患有脂肪肝。这 9 名患者中,只有 3 名有肝肿大。在 9 名受 c.448G>C 突变影响的患者中,有 7 名有脂肪浸润,其中 3 名患者同时有肝肿大。
HFI 患者中脂肪肝的患病率很高,且与肥胖和胰岛素抵抗无关。HFI 患者脂肪肝的诊断,尤其是新的治疗方法的确定,可以对这些患者的生活质量产生积极影响。